Bayer Market Cap 2012-2026 | BAYRY

Bayer market cap history and chart from 2012 to 2026. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares outstanding. Bayer market cap as of September 14, 2026 is $56.08B.
Unlock Macrotrends Premium
40 years of data
Faster, ad-free pages
Unlimited data exports
Full-width charts
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $56.081B $51.552B
Bayer AG is a life science company with core competencies in the areas of health care and agriculture. With the company's focus completely on the Life Science businesses, a new organizational structure was introduced effective Jan 1, 2016. Bayer Group now comprise exclusively of the Life Science businesses. The company started reporting in three segments ' Pharmaceuticals, Consumer Health and Crop Science ' from the third quarter of 2019. Both Animal Health and Currenta were reported as discontinued operations in the quarter. The company acquired U.S. seed giant Monsanto in June, 2018. With the acquisition, Bayer now has the strongest portfolio of seed and crop protection products for a wide range of crops and indications, the best research and development platform and the leading digital farming business.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $1071.528B 36.15
Johnson & Johnson (JNJ) United States $641.804B 24.52
AbbVie (ABBV) United States $462.493B 24.08
Merck (MRK) United States $357.370B 45.12
Roche Holding AG (RHHBY) Switzerland $349.105B 0.00
Novartis AG (NVS) Switzerland $265.214B 16.01
Novo Nordisk (NVO) Denmark $194.004B 10.81
Pfizer (PFE) United States $157.995B 9.09
Sanofi (SNY) France $105.050B 8.84
Innoviva (INVA) United States $1.510B 5.16